Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in Metastatic Melanoma with c-KIT Mutation
NCT00424515Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2006
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in mucosal melanoma, acral lentiginous melanoma (ALM), melanoma, sponsored by Dana-Farber Cancer Institute. Started Jul 2006; status: completed.
02
Drugs
03
Conditions
mucosal melanomaacral lentiginous melanoma (ALM)melanoma
Beyond the preview
Go deeper on NCT00424515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00424515.